Background Myasthenia gravis (MG) is an auto-immune disease, and the mainstay of therapy is immunomodulation. Such patients are at high risk of acquiring any infections. Hence, we sought to determine the impact of the current global pandemic COVID-19 infection in MG patients. Methods For our study, we used Cerner Real-World DataTM that was provided through Cerner’s HealtheDataLab research tool. We ran a database query from January 2019 to July 2020 in our study and identified myasthenia patients with and without COVID-19 infection. To extract these patients’ data, we used ICD 9-CM, ICD-10, and SNOMED-CT codes. We reported the data using means, range, and prevalence rates, and the p-values were calculated using the two-sample t-test and Pearson’s chi-squared test. Results In the COVID-19 data set, a total of twenty-seven myasthenia patients were identified with a positive COVID-19 infection, and four were diagnosed with an exacerbation. The male to female ratio was equal and one unknown gender (3.7%) with a mean (± SD) age of 64.33 ± 18.42 years. This study group was compared with a non-COVID-19 data set in which a total of sixty-four myasthenia patients were identified, and twenty-three had an exacerbation. Among the 13 hospitalized patients in the two groups, the mean length of hospitalization for the myasthenia patients in the COVID-19 data set was 8.28 days (n = 7), and the non-COVID-19 set was 4.33 days (n = 6), and it was statistically significant (p-value= 0.007). Conclusions The mean length of hospital stay is prolonged in myasthenia patients who tested positive for COVID-19.

No abstract

No abstract

No abstract

No abstract

amplitudes of lower limbs with normal conduction velocities. Electromyography of lower limbs was normal.After 3 days of stabilization, clinical evolution was rapidly favorable without treatment.Three months after, residual sensory deficit was present in the feet.Six months after, there were no more symptoms.Diagnostic of pure acute sensory neuropathy associated with SARS-COV-2 disease was retained.This clinical case has been defined as a pure sensory GBS described like an acute monophasic widespread neuropathy characterized clinically by exclusive sensory symptoms progressing in a maximum of 6 weeks. 4 The association between SARS-COV-2 and sensory neuropathy seems obvious based on the time of appearance of neurological symptoms and positive SARS-COV-2 serology (7 days). All other causes of acute sensory neuropathy have been ruled out.The autoimmune nature was suggested by the presence of antiganglioside antibodies. Antibodies found in our patient (GM2 IgM and GD2 IgM) are not classically associated with GBS, but their presence has already been reported in association with sensitive neuropathies with good prognosis. 5 The existence of a pure sensory form of GB syndrome remains controversial, especially because in most cases, a clinical or electrophysiological motor component is found. Our presentation tends nevertheless to confirm existence of this form.

No abstract

Background: Becker and Duchenne muscular dystrophies constitute the most common inherited dystrophinopathies. The chronic steroid treatment predisposes them to any infection, hence, we sought to determine the current COVID-19 infection in them. We conducted an analysis on a real-world database to identify the effect of COVID-19 infection and identified a case of Becker muscular dystrophy who tested positive for COVID-19. For our analysis, we utilized Cerner Real-World DataTM that was provided through Cerner's HealtheDataLab research tool. Case report:  A 63-year-old Caucasian male with Becker muscular dystrophy, hyperlipidemia, and atrial fibrillation, was hospitalized with COVID-19 infection. Our search revealed June 22, 2020, as the patient's COVID-19 service date when tested positive. The patient received antibiotics and supportive therapy during hospitalization. Intricate details like oxygen requirement, blood gas analysis, and mechanical ventilation could not be retrieved if used. The patient developed complications like sepsis, pneumonia, acute respiratory failure that resulted in prolonged hospitalization. Our data reported that the patient was alive during discharge. Conclusion:  Although patient developed complications during hospitalization, no death from the COVID-19 infection was observed in our analysis.